Tiziana Life Sciences Ltd Overview
Pro stress-test →Tiziana Life Sciences is a dual-listed clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. The company is developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy, with innovative nasal, oral and inhalation approaches that have the potential to provide improvements in efficacy as well as safety and tolerability compared to intravenous delivery.
Strategic Profile
Pro stress-test →Tiziana's two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world, with Phase 2 applications in a wide range of autoimmune and inflammatory diseases including nonalcoholic steatohepatitis, ulcerative colitis, multiple sclerosis, type-1 diabetes, Crohn's disease, psoriasis and rheumatoid arthritis.
Competitive Landscape
Pro stress-test →Tiziana competes in the clinical-stage immunotherapy space against larger pharma companies and other biotech firms developing monoclonal antibodies and immunomodulators. Key differentiators include the proprietary non-IV delivery platforms and Foralumab's unique anti-CD3 mechanism. Competitors include established players in autoimmune disease treatment and other biotechs targeting similar indications, though Tiziana's delivery technology offers a distinct positioning.
Industry Context
Tiziana Life Sciences Ltd operates in Biotechnology & Clinical-stage Biopharmaceuticals.
Key facts
Founded: N/A · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: $163M